BioNexus Gene Lab Corp
BGLC- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001737523
No open-market purchases or sales by BioNexus Gene Lab Corp insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $27.2K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BioNexus Gene Lab Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BioNexus Gene Lab Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tan Lee Su-Leng | Chief Executive Officer | 338,709 | Aug 14, 2026 | 1 |
| Yap Chee Keong | Director | 32,258 | Aug 14, 2026 | 1 |
| Bin Abdul Hamid Muhammad Azrul | Director | 32,258 | Aug 14, 2026 | 1 |
| Chong Set Fui | Chief Financial Officer | 96,774 | Aug 14, 2026 | 1 |
| Low Jook Yuen | Director | 17,390 | Aug 14, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.